Skip to Content
Merck
  • Myogenic tissue nanotransfection improves muscle torque recovery following volumetric muscle loss.

Myogenic tissue nanotransfection improves muscle torque recovery following volumetric muscle loss.

NPJ Regenerative medicine (2022-10-21)
Andrew Clark, Subhadip Ghatak, Poornachander Reddy Guda, Mohamed S El Masry, Yi Xuan, Amy Y Sato, Teresita Bellido, Chandan K Sen
ABSTRACT

This work rests on our non-viral tissue nanotransfection (TNT) platform to deliver MyoD (TNTMyoD) to injured tissue in vivo. TNTMyoD was performed on skin and successfully induced expression of myogenic factors. TNTMyoD was then used as a therapy 7 days following volumetric muscle loss (VML) of rat tibialis anterior and rescued muscle function. TNTMyoD is promising as VML intervention.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Thrombin from bovine plasma, ≥60 NIH units/mg protein (biuret)
Sigma-Aldrich
Fibrinogen from bovine plasma, Type I-S, 65-85% protein (≥75% of protein is clottable)